Sai Life Sciences Ltd
Incorporated in 1999, Sai Life Sciences
Ltd carries out contract research and manufacturing activities for customers
engaged in pharmaceutical and bio
technology industries[1]
- Market Cap ₹ 14,523 Cr.
- Current Price ₹ 697
- High / Low ₹ 809 / 635
- Stock P/E 175
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 10.6 %
- ROE 8.89 %
- Face Value ₹ 1.00
Pros
- Debtor days have improved from 83.6 to 63.8 days.
- Company's working capital requirements have reduced from 180 days to 130 days
Cons
- Company has a low return on equity of 3.28% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Part of BSE Allcap BSE Healthcare Nifty 500 BSE SmallCap BSE IPO
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 695 | 760 | 870 | 1,217 | 1,465 | |
| 520 | 593 | 743 | 1,048 | 1,178 | |
| Operating Profit | 176 | 167 | 126 | 169 | 287 |
| OPM % | 25% | 22% | 15% | 14% | 20% |
| 6 | 27 | 28 | 27 | 29 | |
| Interest | 24 | 33 | 54 | 81 | 88 |
| Depreciation | 44 | 80 | 90 | 99 | 119 |
| Profit before tax | 113 | 82 | 10 | 16 | 109 |
| Tax % | 35% | 25% | 36% | 39% | 24% |
| 73 | 61 | 6 | 10 | 83 | |
| EPS in Rs | |||||
| Dividend Payout % | 0% | 0% | 1,117% | 676% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 24% |
| TTM: | 20% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 2% |
| 3 Years: | 11% |
| TTM: | 711% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 3% |
| Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|---|---|
| Equity Capital | 16 | 17 | 18 | 18 | 18 | 19 |
| Reserves | 703 | 845 | 861 | 870 | 957 | 1,027 |
| 249 | 637 | 752 | 933 | 929 | 992 | |
| 247 | 318 | 527 | 358 | 359 | 439 | |
| Total Liabilities | 1,215 | 1,817 | 2,157 | 2,179 | 2,262 | 2,477 |
| 373 | 701 | 751 | 1,037 | 1,180 | 1,228 | |
| CWIP | 116 | 246 | 410 | 151 | 107 | 152 |
| Investments | 0 | 0 | 0 | 2 | 2 | 2 |
| 726 | 870 | 997 | 989 | 973 | 1,095 | |
| Total Assets | 1,215 | 1,817 | 2,157 | 2,179 | 2,262 | 2,477 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| 129 | -36 | 105 | 219 | 263 | |
| -158 | -260 | -102 | -99 | -191 | |
| 268 | 296 | 72 | -201 | -95 | |
| Net Cash Flow | 239 | -1 | 75 | -80 | -24 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2019 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|---|---|
| Debtor Days | 123 | 99 | 102 | 85 | 64 |
| Inventory Days | 86 | 127 | 179 | 121 | 72 |
| Days Payable | 207 | 230 | 279 | 180 | 163 |
| Cash Conversion Cycle | 1 | -4 | 2 | 25 | -28 |
| Working Capital Days | 133 | 249 | 233 | 178 | 130 |
| ROCE % | 3% | 6% | 11% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
2d - Appointment of Mr. Sivaramakrishnan Chittor as Additional Director and CFO on 28 April 2025.
-
Announcement under Regulation 30 (LODR)-Change in Management
23 Apr - COO Sauri Gudlavalleti moves to Head of Special Projects role effective 23 April 2025.
-
Announcement under Regulation 30 (LODR)-Allotment
23 Apr - Allotment of 46,510 shares under ESOP 2008 and 2018 on 23 April 2025.
- Clarification On Increase In Volume 16 Apr
-
Clarification sought from Sai Life Sciences Ltd
16 Apr - Exchange has sought clarification from Sai Life Sciences Ltd on April 16, 2025, with reference to Movement in Volume.
Concalls
-
Feb 2025Transcript PPT
-
Feb 2025TranscriptNotesPPT REC
Business Overview:[1]
a) SLS is a Hyderabad-based contract research development and manufacturing organisation in the pharmaceutical sector with a significant presence in regulatory markets of US and Europe.
b) It offers integrated services across the pharmaceutical lifecycle from discovery services to development and manufacturing of new chemical entities to global innovator pharmaceutical and biotechnology companies.
c) In FY24, company has completed
200+ discovery programmes and 40+ programmes have advanced to clinical
phases.
d) SLS has a fully integrated in-house
synthetic and medicinal chemistry, drug metabolism, biology, pharmacokinetics
and toxicology.
e) In terms of therapy, they have worked in oncology and other key therapy areas include central nervous system, inflammation and anti
virals.
f) SLS provides its services to 17 out of the top 20 global pharmaceutical companies and several biotechnology companies.